Role of Red Cell Distribution Width to Platelet Ratio in Predicting Hepatic Fibrosis in Chronic Hepatitis B

A Ferdous1, A N Ahmed, S A Rahman

  • 1Dr Afroza Ferdous, Assistant Surgeon, Narayanganj Sadar Upazilla Health Complex, Narayanganj, Bangladesh.

Insights

The Red cell distribution width to platelet ratio (RPR) shows a strong association with hepatic fibrosis in chronic Hepatitis B virus (HBV) patients. This non-invasive marker can aid in assessing liver fibrosis stages in HBV-infected individuals.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pathology
  • Medical Diagnostics

Background:

  • Hepatitis B virus (HBV) infection affects over 2 billion people globally, with 400 million chronic carriers at risk of liver cirrhosis and cancer.
  • In Bangladesh, HBV prevalence ranges from 2.3% to 9.7%, with approximately 10 million carriers, driven by factors like lack of health education and vaccination.
  • Accurate assessment of hepatic fibrosis is crucial for managing chronic HBV infection and preventing severe liver disease.

Purpose of the Study:

  • To evaluate the Red cell distribution width to platelet ratio (RPR) as a non-invasive marker for predicting hepatic fibrosis in chronic Hepatitis B virus patients.
  • To determine the correlation between RPR and the stages of hepatic fibrosis.
  • To assess the diagnostic performance of RPR in identifying hepatic fibrosis.

Main Methods:

  • A cross-sectional study involving 40 patients with chronic Hepatitis B virus infection.
  • Measurement of Red cell distribution width (RDW) and platelet count using an automated hematology analyzer.
  • Calculation of RPR and correlation analysis with histopathologically determined stages of hepatic fibrosis; Receiver-Operating Characteristic (ROC) curve analysis was used.

Main Results:

  • A significant positive correlation (Spearman's coefficient = 0.749, p<0.001) was observed between RPR and the stages of hepatic fibrosis in chronic HBV patients.
  • The RPR demonstrated a sensitivity of 62.86%, specificity of 80%, positive predictive value of 95.65%, and negative predictive value of 23.53%.
  • The area under the ROC curve for identifying hepatic fibrosis using RPR was 0.889, indicating strong diagnostic performance.

Conclusions:

  • The Red cell distribution width to platelet ratio (RPR) is strongly associated with the stages of hepatic fibrosis in chronic Hepatitis B patients.
  • RPR emerges as a potentially valuable and non-invasive diagnostic tool for assessing hepatic fibrosis in the context of chronic HBV infection.
  • Further research with larger cohorts is warranted to validate RPR's utility in clinical practice for managing chronic Hepatitis B.

Related Concept Videos

Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
590
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K